Oppenheimer Maintains Outperform on Palvella Therapeutics, Raises Price Target to $232
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Trevor Allred maintains Palvella Therapeutics (NASDAQ:PVLA) with a Outperform and raises the price target from $210 to $232.
Oppenheimer analyst Trevor Allred maintains Palvella Therapeutics (NASDAQ:PVLA) with a Outperform and raises the price target from $210 to $232.